Cargando…

Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: a recommendation from experienced users: A position statement on the use of bioresorbable vascular scaffolds in the Netherlands

Percutaneous coronary interventions (PCI) have become a reliable revascularisation option to treat ischaemic coronary artery disease. Drug-eluting stents (DES) are widely used as first choice devices in many procedures due to their established good medium to long term outcomes. These permanent impla...

Descripción completa

Detalles Bibliográficos
Autores principales: Everaert, Bert, Felix, Cordula, Koolen, Jacques, den Heijer, Peter, Henriques, Jose, Wykrzykowska, Joanna, van der Schaaf, Rene, de Smet, Bart, Hofma, Sjoerd, Diletti, Roberto, Van Mieghem, Nicolas, Regar, Evelyn, Smits, Peter, van Geuns, Robert-Jan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bohn Stafleu van Loghum 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352153/
https://www.ncbi.nlm.nih.gov/pubmed/25626696
http://dx.doi.org/10.1007/s12471-015-0651-3
Descripción
Sumario:Percutaneous coronary interventions (PCI) have become a reliable revascularisation option to treat ischaemic coronary artery disease. Drug-eluting stents (DES) are widely used as first choice devices in many procedures due to their established good medium to long term outcomes. These permanent implants, however, do not have any residual function after vascular healing following the PCI. Beyond this initial healing period, metallic stents may induce new problems, resulting in an average rate of 2 % reinterventions per year. To eliminate this potential late limitation of permanent metallic DES, bioresorbable coronary stents or ‘vascular scaffolds’ (BVS) have been developed. In a parallel publication in this journal, an overview of the current clinical performance of these scaffolds is presented. As these scaffolds are currently CE marked and commercially available in many countries and as clinical evidence is still limited, recommendations for their general usage are needed to allow successful clinical introduction.